Skip to main content

Table 1 Risk adjustment model adopted among men with PCa from clinical registries in SA and Victoria

From: A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease

Variable

NCCN

Low

Clinical T1–T2a stage AND GS 2–6 AND PSA level <10 ng/mL

Intermediate

Clinical T2b–T2c stage OR GS = 7 OR PSA level 10–20 ng/mL

High

Clinical T3a stage OR GS 8–10 OR PSA level >20 ng/mL

Very high (locally advanced)

Clinical T3b–T4

Any T, N1

Metastatic

Any T, Any N, M1

  1. NCCN National Comprehensive Cancer Network, GS Gleason Score, PSA Prostate Specific Antigen
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us